Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: NEFA

Search for Biomarkers

Analyte:

NEFA

Platform:

Matrix:

Human K2 EDTA plasma

Disease State:

Status:

Validated

Required Sample Volume:

50 µL/well

Sensitivity-LLOQ/ULOQ:

LLOQ: 5.20 µM
ULOQ: 333 µM

Biological or Clinical Significance:

Individual fatty acids, free fatty acids (FFA), or the non-esterified fatty acids (NEFA), circulate primarily in association with albumin. They are an important metabolic fuel. Non-esterified fatty acids (NEFA) are the major component of triglycerides, which consist of three fatty acids linked to a glycerol backbone. Hydrolysis of triglycerides in adipose tissue by hormone sensitive lipase liberates NEFAs and glycerol. Low concentrations of NEFAs are normally found in blood. Increased concentrations indicate breakdown of fat (lipolysis), which occurs in response to increased energy demand. NEFAs are considered a biomarker of negative energy balance, where the supply of glucose is insufficient to meet energy needs.

Fatty acids play a central role in providing energy to tissues, particularly during fasting. The liver, kidneys, myocardium, and skeletal muscles, but not the brain. The major storage form of fatty acids is in triglycerides (large amounts are also esterified to cholesterol or in phospholipids), and the enzymes lipoprotein lipase and hepatic lipase hydrolyze the triglycerides to fatty acids and glycerol, thereby releasing them as energy sources for the various tissues. FFA that have been released from triglyceride by the actions of lipoprotein lipase and hepatic lipase are elevated in blood of subjects with central obesity, insulin resistance and type II diabetes.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies